Cancer combo trial pulled before it even started
NCT ID NCT07511972
First seen Apr 22, 2026 · Last updated Apr 28, 2026 · Updated 3 times
Summary
This study was designed to test a new drug, NGM707, combined with pembrolizumab in people with advanced or metastatic solid tumors that could not be removed by surgery. The goal was to see if the combination could shrink tumors and to check for side effects. However, the trial was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRC are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.